Age ≥80 years Weight ≤60 kg Serum creatinine ≥1.5 mg/dL Hepatic impairment Mild: No dosage adjustment required Moderate: Patients may have intrinsic coagulation abnormalities; data are limited and no recommendations are available Severe: Not recommended Dosing Considerations Switching between apixaban ...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
‡ Dashed vertical lines illustrate pharmacokinetic changes that were used to inform dosing recommendations. § No dose adjustment is recommended for nonvalvular atrial fibrillation patients unless at least 2 of the following patient characteristics (age greater than or equal to 80 years, body weight...
Biliary and direct intestinal excretion account for fecal elimination. Half-life: 6 hr (12 hr after repeated dosing due to prolonged absorption). TIME/ACTION PROFILE (effect on hemostasis) ROUTEONSETPEAKDURATION PO unknown 3–4 hr† 24 hr†Blood levels. Contraindication/Precautions ...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...